An announcement from Metagenomi, Inc. (MGX) is now available.
Metagenomi, Inc. and ModernaTX, Inc. have mutually terminated their partnership initially established in 2021 for developing in-vivo genome editing therapies. As a result, Metagenomi reclaims full rights to its genome editing systems. Since the termination, Metagenomi is no longer eligible to receive any future payments from Moderna. Additionally, Metagenomi has updated its investor presentation and plans to discuss these changes in an investor call, signaling a new phase in the company’s strategic direction.
See more insights into MGX stock on TipRanks’ Stock Analysis page.
